evipedia.ai
← Back

Shilajit for Health & Longevity

Evidence Review created on 09/13/2026 using AI4L / Opus 5

Also known as: Mumijo, Mumie, Moomiyo, Mumiyo, Shilajatu, Salajeet, Asphaltum punjabianum, Mineral Pitch, Black Asphaltum, PrimaVie

Motivation

Shilajit is a sticky, tar-like substance that seeps from cracks in high mountain rock across the Himalayas, the Altai, the Caucasus and the Andes. It is formed over centuries as plant material breaks down and compresses between layers of stone, and it is sold today as a resin, powder or capsule. Interest centres on the dark organic acids it contains, best known as fulvic acid, together with a broad spread of minerals.

Traditional Ayurvedic texts place it among the preparations meant to restore strength and slow decline, and Central Asian and Soviet sports medicine used it for fracture healing and recovery. Modern supplement marketing has grown quickly, and with it the number of products of very uneven quality, since the raw material varies with the rock it comes from.

This review examines what controlled human research shows about shilajit’s effects on hormones, bone and muscle, what the analytical literature reports about its mineral and toxic-element content, and how the two sets of findings sit alongside one another.

Benefits - Risks - Protocol - Conclusion

High-level treatments of shilajit from expert platforms and from narrative academic reviews that survey the substance as a whole.

Content from Peter Attia, Chris Kresser, Andrew Huberman and Lifespan.io could not be included: none of those platforms carries an item that treats shilajit at length. Huberman’s only on-record mentions are brief asides within broader fertility discussions, surfaced through a machine-generated clip index rather than a standalone article or episode.

Grokipedia

  • Shilajit

    Broad encyclopedic entry covering geological formation, regional varieties, purification methods and commercial grading, with a candid section on the limits of the clinical evidence and on heavy-metal safety.

Examine

  • Shilajit

    Graded evidence summary with a dosing range drawn from the trials, an explicit safety database covering contamination and drug interactions, and a blunt statement that high-quality human research is scarce.

ConsumerLab

  • Shilajit Supplements Review (Resins and Extracts)

    Independent laboratory testing of eight resins, capsules, liquids and gummies, reporting measured fulvic acid content and lead, cadmium, arsenic and mercury levels, plus a standing update on thallium findings.

Systematic Reviews

Systematic reviews that bear on shilajit, covering the hormonal claim and the preclinical anticancer literature.

The principal risk of shilajit is toxic-element exposure from the material itself. No systematic review or meta-analysis of shilajit’s contamination or safety profile exists, so that side of the trade-off is unrepresented in this section and is covered below from primary analytical studies instead.

Mechanism of Action

Shilajit is not a single molecule but a matrix. Roughly 60–80% of its dry weight is humic substances, chiefly fulvic acids: small polyphenolic carboxylic acids that bind metal ions and ferry them across membranes. About a fifth is mineral matter dominated by calcium, potassium and magnesium, with amino acids (mostly glycine) and phenolic acids such as caffeic and gallic acid making up much of the remainder (Kamgar et al., 2025).

Three mechanisms are proposed. Energy: the dibenzo-α-pyrones and their chromoprotein complexes are redox-active and are thought to shuttle electrons in the mitochondrial respiratory chain, sparing coenzyme Q10 and supporting output of ATP (adenosine triphosphate, the cell’s energy currency). Signalling: shilajit extracts activate Nrf2 (a control switch that turns on a cell’s own antioxidant genes) and suppress NF-κB (a master switch for inflammatory genes) in animal and cell studies. Structure: eight weeks of supplementation upregulated extracellular matrix genes (the scaffold of collagen, elastin and fibronectin around cells) in human muscle biopsies, the proposed route to the bone, tendon and skin findings, in a trial supplied by Natreon, which sells the standardised extract (Das et al., 2016).

A competing reading treats the mineral-carrier role as the whole story, with fulvic acid simply improving absorption of calcium, magnesium and iron, and attributes the remaining findings to small trials. No human pharmacokinetic study has measured absorption, tissue distribution, metabolising enzymes or elimination half-life for any shilajit constituent, so selectivity cannot be stated.

Historical Context & Evolution

Shilajit enters the written record in the Ayurvedic compendia, classed among the preparations given to restore vigour and slow decline. It was prescribed for urinary complaints, wasting conditions and general debility, and always after a purification step in which the raw exudate is dissolved, filtered and sun-dried; the classical texts are explicit that unpurified material is harmful. Parallel traditions ran in Persian medicine, where a bitumen called mumiya was used for fractures and internal injury, and across Central Asia and Siberia, where mumijo carried the same reputation. Soviet sports and military medicine took this up in the mid-twentieth century for recovery and athletic performance.

The modern phase began with Shibnath Ghosal’s chemical work in India in the 1980s and 1990s, which isolated the dibenzo-α-pyrones and fulvic acid fractions and separated them from the mineral load (Agarwal et al., 2007). That characterisation made standardised extracts possible and underpins the branded material used in nearly every subsequent trial.

Opinion has not moved in one direction. A 2011 ethnopharmacological review concluded that the antioxidant work had been done at irrelevant doses without positive controls and that immune claims were unproven. Since then, placebo-controlled trials with bone and hormone endpoints have appeared, while analytical chemistry has documented a toxic-element content that the earlier literature never measured. Both lines remain active, and neither has closed the question.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: no clinical endpoint or validated surrogate has been reproduced across more than one controlled human trial, every positive finding resting on a single randomized trial or on uncontrolled human data, with the only replicated evidence class being gene-expression and biomarker work.

Medium 🟩 🟩

Preservation of Bone Mineral Density After Menopause

Bone density falls after oestrogen withdrawal, driven partly by oxidative stress and inflammation. A 48-week randomized, double-blind, placebo-controlled trial in 60 postmenopausal women with osteopenia (thinning bone short of osteoporosis) found spine and hip density fell on placebo but was preserved dose-dependently on 250 mg or 500 mg daily, alongside falls in CTX-1 (a fragment shed when bone collagen breaks down). One trial, one population, using the maker Natreon’s own extract (Pingali & Nutalapati, 2022).

Magnitude: Lumbar-spine and femoral-neck bone density declined on placebo but rose from baseline on both 250 mg and 500 mg over 48 weeks, the higher dose giving the larger gain, with between-group differences in percentage change significant at 24 and 48 weeks (p < 0.001, meaning a difference this large would be very unlikely to arise by chance); the published report gives significance levels rather than absolute density figures.

Higher Circulating Testosterone in Middle-Aged Men

A 90-day randomized, double-blind, placebo-controlled trial in men aged 45–55 taking 250 mg twice daily raised total testosterone, free testosterone and DHEA-S (dehydroepiandrosterone sulfate, a precursor the body converts into sex hormones) against placebo, while the pituitary signals driving the testes held steady, pointing to a testicular effect. An uncontrolled trial in men with low sperm counts found a similar rise. The product was PrimaVie, supplied by its maker Natreon; nearly the whole human literature shares this commercial origin (Pandit et al., 2016).

Magnitude: Total testosterone rose about 20% over 90 days, from roughly 399 to 475 ng/dL, with free testosterone rising about 19%; the uncontrolled trial in men with low sperm counts reported a 23.5% rise on a lower dose.

Faster Healing of a Broken Bone

Persian and Central Asian practice used shilajit for fractures, and the proposed route is the same collagen and mineral scaffolding seen in the muscle and skin work. A randomized, double-blind, placebo-controlled trial in 160 adults with a fresh tibia (shinbone) fracture gave 1000 mg daily for 28 days after surgery and shortened the time to bone union against placebo, with no difference in reported adverse effects. One trial, one fracture type, no replication, and unlike the hormone and bone work it carries no manufacturer involvement (Sadeghi et al., 2020).

Magnitude: Mean time to tibial union was 129 days on 1000 mg daily versus 153 days on placebo, a difference of roughly 24 days (p < 0.049).

Low 🟩

Exercise Performance and Fatigue Resistance ⚠️ Conflicted

Two lines disagree. A randomized placebo-controlled trial in 63 young men found 500 mg daily preserved strength after fatiguing exercise, but only in the stronger half of the sample (Keller et al., 2019). A 28-day uncontrolled study reported broad gains. Net reading: a narrow subgroup effect, the open-label gains unreliable.

Magnitude: In the stronger half of the trial sample, strength decline after fatiguing exercise was 8.9% on 500 mg daily versus 16.0% on placebo; the whole-sample comparison was null.

Improved Semen Parameters in Men With Low Sperm Counts

An open-label trial gave 100 mg twice daily for 90 days to 28 men with counts below 20 million per millilitre. Count, motility and normal forms improved and seminal oxidative damage fell. No control group, so natural fluctuation is not excluded (Biswas et al., 2010).

Magnitude: Total sperm count rose 61.4%, semen volume 37.6%, normal forms 18.9% and motility 12.4–17.4% depending on the time point, all against each man’s own baseline rather than a placebo group.

Lower Inflammatory Signalling

High-sensitivity C-reactive protein (a blood marker of general inflammation) fell progressively over 48 weeks in both shilajit arms of the bone trial and not on placebo, alongside shifts in unvalidated oxidative markers. A 28-day uncontrolled study reported a similar fall (Pingali & Nutalapati, 2022).

Magnitude: The uncontrolled study reported a 25.4% fall in C-reactive protein over 28 days; the controlled trial reports significant percentage reductions from baseline versus placebo without publishing absolute values.

Glucose and Lipid Markers ⚠️ Conflicted

A 12-week randomized trial in 109 people at metabolic risk showed signals for insulin sensitivity and lipids, but shilajit sat at only 6–12 mg inside a chromium and amla blend, so nothing is attributable to it (Martinez et al., 2025). Net reading: no isolated trial supports a glycaemic benefit.

Magnitude: Not quantified in available studies. No trial has tested shilajit alone against placebo on fasting glucose, insulin sensitivity or lipids; the available figures come from a blend in which shilajit was a minor component.

Speculative 🟨

Connective-Tissue and Microvascular Remodelling

Human evidence stops at biomarkers: muscle and skin biopsies show scaffold genes switched on, and skin microperfusion improves. No trial has measured skin, tendon or wound outcomes (Das et al., 2019).

Cognitive Protection

Basis is preclinical only: fulvic acid blocks tau protein clumping in cell-free assays and Andean shilajit protects neurons in disease models. No controlled human cognitive trial exists (Carrasco-Gallardo et al., 2012).

Anticancer Activity

Nine preclinical studies show dose-dependent killing of cancer cell lines with relative sparing of normal cells. All in-vitro bar one rat model; no human study of any design exists (Das et al., 2026).

Benefit-Modifying Factors

  • Baseline testosterone: The hormonal signal was found in men aged 45–55 with age-typical decline and in men with low sperm counts. Men already in the upper part of the reference range have no trial evidence of any further rise.

  • Baseline bone density: The bone trial enrolled women with osteopenia, whose bone loss was actively accelerating. Effects on people with normal density, or on men, have never been tested.

  • Baseline muscular strength: The strength effect appeared only in the stronger half of the trial sample. Whether that reflects greater connective-tissue turnover in stronger men or a chance subgroup split is unresolved.

  • Sex: Benefits have been tested sex-separately, never head to head. Bone data come from women only; hormone, sperm and strength data from men only. Whether either translates across sexes is unknown.

  • Age: Every positive trial ran in adults aged 18–65. Nothing addresses people beyond 65, where mineral handling, kidney clearance of absorbed metals and fracture risk all differ materially.

  • Genetic variation in mineral handling: Carriers of HFE C282Y or H63D (variants that increase iron absorption) may take up more of shilajit’s iron and mineral load than intended, shifting the balance of effect toward accumulation.

  • Pre-existing conditions: Chronic kidney disease reduces clearance of absorbed trace elements; inflammatory conditions raise the baseline C-reactive protein against which any anti-inflammatory effect would be measured.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no adverse outcome has been documented in more than one controlled human trial, the controlled trials reporting tolerability and normal laboratory panels only, and the substantive safety literature consisting of product-composition analyses and one isolated case report rather than replicated human adverse-event data.

Medium 🟥 🟥

No risk reaches Medium either: the evidence class that falls short is trial-collected adverse-event reporting, which exists but is uniformly negative in samples of 25 to 63 people followed for 4 to 48 weeks, so no single controlled trial and no consistent observational dataset has captured an adverse clinical outcome.

Low 🟥

Toxic Element Content of Commercial Product

Shilajit carries the geology it formed in. Analyses find lead, arsenic, cadmium, mercury and thallium in raw material and finished supplements, most below herbal limits but some above, and thallium ran higher in several supplements than in the crude exudate (Kamgar et al., 2025).

Magnitude: Thallium reached 0.226 µg/g in raw shilajit and 0.5 µg/g in supplements, up to 0.095 µg per capsule; a 2024 review counted around 65 metals present, mostly below World Health Organization and Food and Drug Administration herbal limits, with exceedances in a minority of samples.

Gastrointestinal Upset and Headache

The most commonly logged complaints in human use are mild digestive discomfort and headache, consistent with the mineral and acid load of a concentrated resin. Trials of 4 to 48 weeks report no serious adverse events and unchanged liver, kidney and blood panels (Stohs, 2014).

Magnitude: Not quantified in available studies. No trial has reported incidence rates for individual minor adverse events, and the largest samples are too small to estimate frequencies below roughly one in twenty.

Unwanted Androgen Elevation

The hormonal shift counted as a benefit is a hazard where androgen exposure is unwanted: prostate disease under surveillance, androgen-driven hair loss, acne, or women whose cycle regularity a sustained testosterone rise could disturb. The single controlled trial measured the rise, not its consequences (Pandit et al., 2016).

Magnitude: Total testosterone rose about 20% and free testosterone about 19% over 90 days in middle-aged men; no trial has measured androgen response in women, so the size of any shift in them is unknown.

Licorice-Like Blood Pressure and Potassium Disturbance

A pregnant woman developed persistent high blood pressure and low blood potassium after six months of mumijo, resolving on withdrawal — pseudohyperaldosteronism (cortisol escapes normal inactivation and acts as a salt-retaining hormone). It is the only such report, and no trial has monitored for it (Stavropoulos et al., 2018).

Magnitude: Not quantified in available studies. A single case report cannot give an incidence, and no controlled trial has tracked blood pressure or potassium during shilajit use.

Speculative 🟨

Mycotoxin and Microbial Contamination of Unpurified Resin

Classical practice insists on purification before use, and the review literature flags fungal toxins and microbial load in raw exudate. No human case series documents illness; the concern rests on origin and tradition.

Iron and Mineral Loading

Shilajit supplies iron and trace elements in a fulvic-acid matrix proposed to raise their uptake. In iron-overload disorders this could accelerate accumulation. No human study has measured iron status during supplementation.

Kidney Stone Formation

The mineral load of a daily resin dose has been raised as a theoretical stone risk in susceptible people. No trial has measured urinary supersaturation, and no case report links shilajit to stones.

Risk-Modifying Factors

  • Iron-handling genotype: HFE C282Y and H63D carriers absorb more dietary iron; shilajit’s iron content plus fulvic acid’s carrier action could compound accumulation in a population already prone to it.

  • Lead-handling genotype: ALAD variants (the gene encoding an enzyme in haem synthesis that also binds lead) alter how lead distributes between blood and bone, changing the consequence of a given contaminated dose.

  • Baseline blood lead and ferritin: Anyone starting with an elevated blood lead level or ferritin above about 300 ng/mL has less headroom before a contaminated product becomes clinically relevant.

  • Sex: Women have no trial-derived adverse-event data at all. Menstruating women lose iron and are less exposed to loading; conversely the androgenic shift is more likely to be unwelcome.

  • Pre-existing conditions: Reduced kidney function slows clearance of absorbed trace elements. Haemochromatosis and thalassaemia (inherited disorders that load the body with iron), and hormone-sensitive prostate disease, each convert an unremarkable exposure into a meaningful one.

  • Age: Kidney filtration declines with age, and lifetime lead burden is already stored in bone, so an added exposure in later decades adds to a larger existing stock than in younger adults.

Key Interactions & Contraindications

  • Blood-glucose-lowering drugs (metformin, glipizide, insulin, empagliflozin): Caution; additive glucose lowering has been seen in animal work and one human trial, risking hypoglycaemia (blood sugar falling too low). More frequent glucose monitoring in the first month is the stated mitigation.

  • Mineral-chelated antibiotics (ciprofloxacin, levofloxacin, doxycycline, minocycline): Caution; the calcium, magnesium and iron in shilajit bind these drugs in the gut and cut absorption, risking treatment failure. Doses separated by at least four hours mitigate this.

  • Levothyroxine and bisphosphonates (bone-density drugs such as alendronate, risedronate): Caution; both are inactivated by co-ingested minerals, risking under-treatment of thyroid or bone disease. A four-hour separation is the standard mitigation.

  • Over-the-counter iron and mineral products (ferrous sulfate, calcium carbonate antacids, magnesium hydroxide): Monitor; additive mineral intake plus fulvic-acid-enhanced uptake risks iron accumulation and, with antacids, unpredictable absorption of both. Two-hour spacing is the usual mitigation.

  • Over-the-counter stomach-acid reducers — proton pump inhibitors and H2 blockers (omeprazole, famotidine): Monitor; less stomach acid means less of shilajit’s mineral fraction dissolves and is absorbed, making the dose response inconsistent rather than harmful.

  • Testosterone-support supplements (tongkat ali, ashwagandha, boron, fenugreek): Caution; effects on testosterone and sex hormone-binding globulin are additive, so stacking can push androgens further than any single agent’s trials tested.

  • Glucose-lowering supplements (berberine, chromium, cinnamon extract, alpha-lipoic acid): Caution; additive glucose lowering, the same hypoglycaemia risk as with prescription agents. Stacking carries that risk in anyone already on a glucose-lowering drug.

  • Coenzyme Q10: Monitor only; the pairing is promoted as synergistic on mitochondrial energy output, with the evidence entirely preclinical. No adverse consequence is documented; the interaction is one of claimed benefit.

  • Testosterone replacement therapy and other exogenous androgens: Caution; shilajit’s effect appears to act at the testis, which exogenous androgens already suppress, so the combination adds androgen load without adding the trial-supported mechanism.

Populations who should avoid Shilajit:

  • Pregnant and breastfeeding women — no human safety data of any kind, and a contaminant load that crosses the placenta.
  • Hereditary haemochromatosis, thalassaemia, or ferritin above 300 ng/mL with transferrin saturation above 45%.
  • Blood lead level at or above 3.5 µg/dL, the current reference value for elevation.
  • Active or previously treated hormone-sensitive prostate cancer, or prostate-specific antigen above 4 ng/mL under surveillance.
  • Chronic kidney disease at stage 3b or worse (estimated filtration rate below 45 mL/min/1.73 m²).
  • Children and adolescents under 18 — no trial has enrolled them.

Risk Mitigation Strategies

  • Third-party tested, batch-specific product: A certificate of analysis from the exact lot for lead, arsenic, cadmium, mercury and thallium mitigates the toxic-element exposure that is shilajit’s principal hazard.

  • Total lead intake below 0.5 µg/day: California Proposition 65’s warning threshold is a usable ceiling; the certificate’s lead figure multiplied by the daily gram dose gives that exposure, preventing cumulative lead accumulation.

  • Purified, standardised extract rather than raw resin: Extracts standardised to at least 50% fulvic acid have been through documented processing, mitigating the fungal toxin, microbial and free-radical load attributed to unpurified exudate.

  • Baseline then 3-month blood lead and ferritin: Measuring before starting and again at 12 weeks catches accumulation from a contaminated batch early, mitigating both lead burden and iron loading in undiagnosed carriers.

  • A daily ceiling of 500 mg: The hormone, bone and strength trials used 250–500 mg daily; higher doses add contaminant exposure in direct proportion for a marginal evidence gain, mitigating avoidable toxic-element intake.

  • Four-hour separation from medication: Taking shilajit at least four hours from thyroid hormone, bisphosphonates and mineral-chelated antibiotics mitigates the absorption loss that would otherwise undertreat the underlying condition.

  • Men over 45: prostate-specific antigen before starting: A baseline measurement before a deliberate 20% androgen rise mitigates the risk of driving undetected hormone-sensitive prostate disease unmonitored.

Therapeutic Protocol

  • Standard regimen: 250 mg twice daily, morning and evening, of a purified extract standardised to at least 50% fulvic acid and around 10% dibenzo-α-pyrones. This is the dose used in the hormone, bone and skin trials.

  • Higher-dose variant: 500 mg once or twice daily. The strength trial and the higher arm of the bone trial used 500 mg daily; 1000 mg daily has been used for eight weeks in a collagen-marker trial without incident.

  • Traditional resin approach: A rice-grain-sized portion of purified resin, roughly 300–500 mg, dissolved in warm water or milk once daily. Ayurvedic practice, not trial-derived, and dose accuracy is poor.

  • Choosing between approaches: The standardised extract carries the trial evidence and a known fulvic acid content; the resin carries the traditional record and a lower price. Neither has been tested against the other.

  • Who popularised each: The standardised extract descends from Shibnath Ghosal’s chemical characterisation and is commercialised by Natreon as PrimaVie, which supplied most trials. The resin route follows classical Ayurvedic preparation, marketed by houses such as Banyan Botanicals.

  • Time of day: No trial compared timings. Morning and early-evening dosing is conventional, on the reasoning that a mitochondrial-energy effect is unwanted near bedtime; no human sleep data support or refute this.

  • Half-life: Unknown. No human pharmacokinetic study has measured the elimination half-life of fulvic acid or the dibenzo-α-pyrones, which is precisely why twice-daily dosing was adopted by convention rather than by calculation.

  • Single versus split dosing: Trials split the daily dose in two, including the 500 mg and 1000 mg arms. Split dosing is the evidenced pattern; once-daily has only been used in the resin tradition.

  • Genetic factors: Carriers of HFE C282Y or H63D, or of ALAD variants affecting lead distribution, have reason to use the lowest effective dose and a certified low-metal product rather than to adjust the schedule.

  • Sex differences: Doses are identical in the male and female trials, 250–500 mg daily. No dose-response work exists in women outside the bone trial, and no trial has compared the sexes directly.

  • Older adults: No trial enrolled anyone beyond 65. Starting at 250 mg daily rather than 500 mg is the conservative course where kidney filtration is reduced and lifetime metal burden is higher.

  • Baseline biomarkers: Low-normal testosterone, osteopenia on bone scan, or a raised C-reactive protein define the states in which an effect has actually been demonstrated; normal values predict nothing measurable.

  • Pre-existing conditions: Reduced kidney function, diabetes on glucose-lowering medication and iron-overload disorders each argue for a lower dose, closer laboratory follow-up, or avoidance rather than a modified schedule.

Discontinuation & Cycling

  • Duration of use: No trial ran beyond 48 weeks, so continuous lifelong use is untested. Shilajit is best treated as a defined course with a measured endpoint, not an indefinite daily addition.

  • Withdrawal effects: None documented. No trial reported rebound in testosterone, bone markers or strength after stopping, and no case report describes a discontinuation syndrome.

  • Tapering: Not applicable. Because no withdrawal effect has been observed and no receptor adaptation is proposed, abrupt discontinuation is the pattern used at the end of every trial.

  • Cycling for efficacy: No evidence supports cycling. The bone effect grew steadily over 48 weeks of uninterrupted use, arguing against interruption; common 8-weeks-on, 2-weeks-off schedules are a marketing convention.

  • Cycling to limit exposure: The defensible reason to pause is cumulative toxic-element intake, not tolerance. Periodic breaks with a blood lead check are a contamination-control measure rather than an efficacy one.

Sourcing and Quality

  • Standardised extract versus raw resin: Extracts specify fulvic acid content and dibenzo-α-pyrone content and carry the clinical evidence. Raw resin bought from marketplaces has neither specification nor documented purification, and composition varies with the source mountain range.

  • Third-party testing is the deciding variable: The document that matters is a lot-specific certificate showing lead, arsenic, cadmium, mercury and thallium measured by inductively coupled plasma mass spectrometry (a method that reads metals down to parts per billion). Generic “lab tested” claims mean nothing.

  • The fulvic acid assay matters: Many labels quote fulvic acid measured by colour-based methods that also capture unrelated humic material and overstate content. Independent testing has found large gaps between labelled and measured amounts.

  • Certification marks that carry weight: United States Pharmacopeia and NSF International verify identity and contaminant limits; Banned Substances Control Group certification matters for anyone tested in sport. None is common in this category.

  • Brands with published independent test data: ConsumerLab has tested Nootropics Depot, Swanson, Banyan Botanicals, Youtheory, Cymbiotika and others, publishing measured fulvic acid and heavy-metal figures. It funds itself by subscription, not manufacturer payment.

  • Regional origin matters: Elemental and phenolic content differs measurably between Himalayan, Altai, Iranian and Kyrgyz material. A supplier that cannot state the origin region cannot support any claim about composition.

  • Gummies and drink mixes underdose: These typically carry a fraction of the trial dose behind a proprietary blend, so the labelled shilajit content is unverifiable and almost always far below 250 mg.

Practical Considerations

  • Time to effect: Hormone changes were measured at 90 days, collagen and strength markers at 8 weeks, and bone density only at 24 and 48 weeks. Nothing meaningful is assessable before three months.

  • Pitfall — buying raw resin on price: The cheapest resin is the least processed and the least tested. Contaminant load and fulvic acid content both track processing, so price differences usually reflect real quality differences.

  • Pitfall — trusting “gold grade” and altitude claims: Grading language such as gold grade, or sourcing claims above 16,000 feet, has no analytical definition and no regulatory meaning. Only a certificate of analysis distinguishes products.

  • Pitfall — stacking with other testosterone-support supplements: Combining shilajit with tongkat ali, boron and ashwagandha pushes androgens past the exposure any trial tested, and makes it impossible to attribute either a benefit or a side effect.

  • Regulatory status: In the United States shilajit is a dietary supplement under the Dietary Supplement Health and Education Act, needing no pre-market approval. It is a licensed Ayurvedic drug in India. The World Anti-Doping Agency does not prohibit it.

  • Payer incentives: No insurer or national health system reimburses shilajit or funds trials of it, while the comparators for its main claims, testosterone replacement and bisphosphonates, are reimbursed. The structural incentive leaves shilajit’s evidence base to its manufacturers.

  • Cost and access: Standardised extract costs roughly $20–40 per month and is freely available; certified low-metal product sits at the upper end. Cost is not a meaningful barrier, but verified quality is scarce.

Interaction with Foundational Habits

  • Sleep: None documented; no trial has collected human sleep data. The only mechanistic hint is preclinical: shilajit activates glycine receptors on hypothalamic neurons in mice, which would be sedating rather than stimulating. Evening dosing is nonetheless conventionally avoided on the unproven assumption of an energising effect.

  • Nutrition: Direct and two-way. Fulvic acid chelates minerals, so shilajit taken with an iron- or calcium-rich meal changes the uptake of both. Taking it with food reduces the digestive discomfort that is the commonest complaint; separate it from a deliberate iron supplement by two hours.

  • Exercise: Potentiating. In the muscle-biopsy study, four weeks of added exercise amplified the scaffold-gene response seen with supplementation alone, and the strength trial’s effect appeared only after fatiguing exercise. No trial supports a benefit without training.

  • Stress management: None established, despite the traditional framing as a stress-adaptation aid. No human trial has measured cortisol, perceived stress or sleep quality. The one relevant human finding is reduced C-reactive protein over 48 weeks, which is downstream of inflammation rather than of the stress response itself.

Monitoring Protocol & Defining Success

Baseline testing serves two purposes: establishing whether the states in which shilajit has shown an effect are present, and fixing a reference point for contaminant exposure. A baseline covers total and free testosterone with DHEA-S in men, a full blood count, a metabolic panel covering liver enzymes, creatinine and estimated kidney filtration rate, high-sensitivity C-reactive protein, fasting glucose with HbA1c (average blood sugar over three months), ferritin with transferrin saturation, uric acid, blood lead, and prostate-specific antigen in men over 45. A bone density scan is added where bone loss is a concern.

Ongoing monitoring runs at 12 weeks for blood lead, ferritin, liver and kidney panels and hormones, then every 6 months while use continues. Glucose deserves closer watching in the first month if a glucose-lowering drug is in use. A bone density scan repeats no sooner than 12 months, since the trial found nothing before 24 weeks.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Total testosterone (men) 600–900 ng/dL The primary trial-supported endpoint Fasting draw before 10 a.m.; conventional labs call 300 ng/dL normal, well below the functional target. Paired with free testosterone and SHBG (sex hormone-binding globulin, the carrier protein that keeps testosterone inactive)
Free testosterone (men) 15–25 pg/mL The bioavailable fraction that rose in trial Calculated or equilibrium dialysis; same morning fasting draw as total testosterone
DHEA-S 200–400 µg/dL (men), 100–250 µg/dL (women) Rose alongside testosterone in the hormone trial Morning draw; declines steeply with age, so it is read against age-matched rather than laboratory-wide ranges
Blood lead Below 1.0 µg/dL Direct readout of the main contamination hazard No fasting needed. The conventional reference value for elevation is 3.5 µg/dL, far above the functional target used here
Ferritin 50–150 ng/mL Detects iron loading from the mineral fraction Rises with inflammation, so it is read alongside C-reactive protein. Conventional upper limits reach 300–400 ng/mL
Transferrin saturation 20–40% Separates true iron loading from inflammatory ferritin rise Fasting morning draw; above 45% with high ferritin warrants iron-overload workup before continuing
High-sensitivity C-reactive protein Below 1.0 mg/L The inflammatory marker that moved in the bone trial Invalid within two weeks of infection or hard training. Conventional labs flag only above 3.0 mg/L
Fasting glucose 75–86 mg/dL Catches additive glucose lowering with medication 8–12 hour fast. Conventional labs flag only above 99 mg/dL. Paired with HbA1c, functional target 4.8–5.3% against a conventional cut-off of 5.7%
ALT Below 26 U/L (men), below 22 U/L (women) Confirms the liver tolerance trials reported ALT is alanine aminotransferase, an enzyme released when liver cells are damaged. Conventional upper limits near 40–50 U/L are too permissive. Drawn with the full metabolic panel
Creatinine and estimated filtration rate Filtration rate above 90 mL/min/1.73 m² Reduced clearance concentrates absorbed trace elements Conventional reporting flags only below 60 mL/min/1.73 m², far below the functional target. Heavy protein intake and creatine loading in the 48 hours before the draw distort the result
Uric acid 3.5–5.5 mg/dL Tracks the theoretical stone and gout concern Conventional upper limits reach 7.0 mg/dL in men and 6.0 mg/dL in women. Fasting draw; rises with dehydration and alcohol, so conditions are standardised between measurements
Prostate-specific antigen (men over 45) Below 2.5 ng/mL, stable year to year Guards the deliberate androgen rise Conventional labs flag only above 4.0 ng/mL. Cycling, ejaculation and prostate examination within 48 hours beforehand raise the value. Trend matters more than any single value
Bone density T-score (lumbar spine, femoral neck) Above −1.0 The endpoint the bone trial actually moved T-score expresses how far density sits from a young-adult average. Repeated on the same scanner no sooner than 12 months
Urinary arsenic and thallium No established target for supplement users; the informative measure is the change from an individual’s own pre-supplement baseline Confirms whether a specific product is adding exposure Only informative as a paired before-and-after on one product and one lot; seafood within 72 hours confounds an arsenic measurement

Qualitative markers worth tracking alongside the laboratory work:

  • Perceived exertion during a repeated, standardised training session
  • Recovery time between hard training sessions
  • Daytime energy stability, particularly mid-afternoon
  • Libido and morning erections in men
  • Digestive comfort in the first two weeks, the window in which complaints appear
  • Headache frequency against a pre-supplement baseline
  • Skin texture and hydration, the one cosmetic endpoint with any human data behind it

Emerging Research

  • Biological age and detoxification trial: NCT07579845, recruiting since May 2026, 60 participants, single-arm, testing a humic and fulvic acid supplement against epigenetic age markers, inflammation and oxidative stress. Its primary endpoint is a commercial epigenetic clock rather than a clinical outcome.

  • Skin trial results now public: NCT02762032, the 45-woman Ohio State skin study, posted full results in June 2026, a decade after enrolment. Independent scrutiny of the perfusion and gene-expression data could firm up or deflate the connective-tissue claim.

  • Metabolic-syndrome combination trial: NCT06641596 tested chromium with Phyllanthus emblica and shilajit in 112 people. Because shilajit was a minor blend component, any follow-up isolating it would be the first real test of a metabolic claim.

  • Contamination chemistry could weaken the case: Kamgar et al., 2026 characterised metals and molecular-weight distribution across twelve regional samples, finding most metals bound in low-molecular-weight humic complexes. Whether that binding raises or lowers absorption of toxic elements is the decisive open question.

  • Gut microbial effects, direction unknown: Kamgar et al., 2026 found shilajit samples from different regions diverged sharply in their effect on gut bacteria and on β-glucuronidase (a bacterial enzyme that returns already-processed hormones and toxins to circulation). One sample worsened what others improved.

  • Resin formulations entering trials: Yadav et al., 2026 ran the first clinical study of traditional resin rather than standardised extract, uncontrolled and manufacturer-run, and called for randomized replication. Whether resin performs like extract is untested.

  • Oncology remains preclinical: Das et al., 2026 found no eligible clinical study in a systematic search. Any first-in-human study would be the single largest change to the evidence base, in either direction.

  • The unfunded questions: No trial has measured human pharmacokinetics, none has enrolled anyone over 65, none has compared resin against extract, and none has followed anyone beyond 48 weeks. Each gap sits where a commercial sponsor has no incentive to look.

Conclusion

Shilajit is a mineral-rich tar-like substance with a long record of traditional use and a small, uneven body of modern human evidence. The strongest signals come from controlled trials in three narrow settings: bone density in women after menopause, testosterone in middle-aged men, and healing time after a broken shinbone. Each rests on a single trial, and the first two were funded or supplied by the company that sells the standardised extract used in them, a pattern that runs through almost the whole clinical literature and that limits how much weight those findings can carry. Beyond these, the human data thin out quickly into small studies without a comparison group and laboratory measurements whose link to how anyone actually feels or functions is unestablished.

The safety picture is unusual. Shilajit itself is well tolerated in the short trials that exist, with little more than occasional stomach upset and headache reported. The concern is the material rather than the molecule: because it is scraped from rock, its composition tracks its geology, and analyses repeatedly find lead, arsenic, cadmium, mercury and thallium in commercial products, sometimes above what testing programmes accept. Product-to-product variation is wide enough that two jars labelled identically may differ substantially in both active content and contaminant load.

What follows is a split verdict rather than a single one: a plausible but thinly evidenced set of effects, attached to a product category whose quality is the dominant variable.

Top - Benefits - Risks - Protocol